Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) has been ...